Protease nexin-1 (PN-1)/glia-derived nexin (GDN) is a member of the Serpin (serine proteinase inhibitor) family, and can inhibit thrombin, plasmin, and plasminogen activators. PN-1 has been shown to be a neuroprotective factor in a number of assay systems, and this activity has been assumed to be a function of its protease inhibitory function. Here, we report cloning and characterization of a Xenopus orthologue of PN-1 (xPN-1). xPN-1 was isolated in a functional screen of an egg cDNA library for factors that modify early axial patterning. xPN-1 is expressed maternally through late tadpole stages, and is expressed preferentially in the notochord, the pharyngeal endoderm, the otic vesicle, and the ventral region of the brain in tailbud embryos. Over-expression of xPN-1 causes defective gastrulation, inhibits convergent extension movements in activin induced animal caps, and inhibits expression of a distinct subset of activin induced mesendodermal markers. Interestingly, expression of point or deletion mutation of the Reactive Center Loop of xPN1,which is essential for the protease inhibitory activity of all serpins, had effects on Xenopus development indistinguishable from those of wild type xPN-1. These observations suggest the possibility that xPN-1 has a novel activity in addition to its established function as an inhibitor of serine proteases. q
Introduction
The serpins (serine protease inhibitor) are a superfamily of serine protease inhibitors conserved in both vertebrates and invertebrates (Gettins, 2002; Irving et al., 2000; Silverman et al., 2001) . Extensive research has focused on the role of Serpin family proteins as effective inhibitors of specific target proteases (reviewed in Gettins, 2002; Ye and Goldsmith, 2001) . Most of Serpin proteins show serine protease inhibitory activity, and have the reactive centre loop (RCL) active site that interacts with target serine proteases. The RCL is a flexible peptide region containing the scissile peptide bond (P1-P1 0 ) targeted by serine proteases. The C-terminus residue (P1) in the cleaved RCL makes a covalent acyl-bond to the catalytic serine residue of the protease, giving irreversible inhibition. While the major function of serpins is associated with this ability to regulate serine proteases, protease inhibition-independent functions have also been proposed for several serpins (Gettins, 2002; Potempa et al., 1994; Silverman et al., 2001 ). This class of Serpin includes hormone-binding serpins, corticosteroid binding globulin (CBG) and thyroxine binding globulin (TBG), a tumor suppressor, maspin, and pigment epithelium-derived factor (PEDF).
Most notably, pigmented epithelium derived factor (PEDF) is a serpin family member that lacks any protease inhibitory activity and has been intensively studied as a potent neuroprotective and anti-angiogenic factor (Dawson et al., 1999; Steele et al., 1993; Tombran-Tink and Barnstable, 2003) . PEDF does not show the typical conformational change seen in the inhibitory Serpins following proteolytic cleavage, and the neuroprotective activity of PEDF is independent of the RCL (Becerra et al., 1995) . Previous studies also showed that PEDF binds to the cell surface to promote activation of NF-kB in cerebellar granule cells (Aymerich et al., 2001; Yabe et al., 2001) . While these biological activities of PEDF are thought to Mechanisms of Development 123 (2006) (Baker et al., 1980; Gloor et al., 1986; Irving et al., 2000; Low et al., 1981; Silverman et al., 2001; Sommer et al., 1987) . PN-1 is secreted, shares common domain structures with other inhibitory Serpins, and can inhibit thrombin, plasmin, and plasminogen activators (Stone et al., 1987) . PN-1 is expressed in various adult tissues; highly in the brain, the bone, the seminal vesicle, the cauda epididymis and the ovary (Choi et al., 1990; Mansuy et al., 1993; Reinhard et al., 1988; Simpson et al., 1994; Vassalli et al., 1993; Wagner et al., 1993) . PN-1 has an anti-apoptotic effect on cultured neuronal cells, and its expression is up-regulated in the brain by injury or ischemia (Meier et al., 1989; Nitsch et al., 1993; Vaughan and Cunningham, 1993) . The potential functions of PN-1 are proposed to be neurotrophic support and inhibition of cell death during brain injury or alteration of the blood-brain barrier (Diaz-Nido et al., 1991; Gurwitz and Cunningham, 1990; Hoffmann et al., 1992; Houenou et al., 1995; Monard et al., 1983; Simpson et al., 1994; Vaughan and Cunningham, 1993; Vaughan et al., 1995; Zurn et al., 1988; reviewed in Turgeon and Houenou, 1997) . While the neuroprotective effects of PN-1 have been assumed to be associated with its protease inhibition activity, this has not been tested. The similarity of this function with that of non-inhibitory serpin PEDF raises the possibility that PN-1 may have biochemical functions separate from its activity as a protease inhibitor (Tombran-Tink and Barnstable, 2003) .
We report here the identification, characterization, and biological activity of a Xenopus orthologue of PN-1 (xPN-1) expressed during early embryogenesis. xPN-1 mRNA is present maternally, and is expressed zygotically through late tadpole stages. It is expressed in the notochord, the pharyngeal endoderm, the otic vesicle and the ventral region of the brain at tailbud to tadpole stages. Ectopic expression of xPN-1 on the prospective dorsal side of the embryo causes severe defects in gastrulation movements, but has relatively little effect when injected on the prospective ventral side. Ectopic xPN-1 also inhibits the convergent extension movements associated with elongation of animal caps induced by activin, and inhibits the expression of a discrete subset of activin-induced genes. Interestingly, identical effects on embryonic phenotype and mesendoderm genes expression are observed following expression of xPN-1 point or deletion mutants that lack the RCL site necessary for protease inhibition activity. These results indicate that xPN-1 may, like PEDF, have a biological activity distinct from its protease inhibitory activity, and that this activity may be important in early embryogenesis.
Results and discussion

Cloning and expression of X. laevis PN-1
To identify novel maternal genes important in early embryonic patterning, we did an ectopic expression screen using mRNAs transcribed in vitro from cDNAs pooled from a full-length normalized Xenopus laevis egg cDNA library. Pools with effects on embryonic patterning were then subdivided to obtain individual clones that modify patterning. One of these cDNA clones caused no obvious general toxicity but resulted in severe defects in gastrulation movements. Sequencing of this clone identified it is Xenopus orthologue of protease nexin-1 (PN-1)/glia-derived nexin (GDN)/SERPINE2 (Fig. 1A) . The overall sequence identity at the amino acid level was 71.3% between Xenopus PN-1 and mouse PN-1, and 75.5% between Xenopus PN-1 and a partial cDNA encoding predicted amino acids 156-397 of chick Pn-1. During development, Xenopus PN-1 transcripts were detected maternally and decreased after Stage 11, but remained detectable through tadpole stages (stage 45) in RT-PCR analysis (Fig. 1B) . Spatially, xPN-1 was expressed in all animal, marginal and vegetal parts of blastula embryos at the late blastula stage ( Fig. 2A) , and the expression became restricted to the prospective neural ectoderm by the end of gastrulation ( Fig. 2B ). At neurula stages, xPN-1 started to be expressed in the notochord, while expression in the neural ectoderm disappeared (Fig. 2C,D) . From tailbud to tadpole stages, xPN-1 was strongly expressed in the notochord, the otic vesicle, the pharyngeal endoderm, and the floorplate of brain ( Fig. 2E-Q) . Expression of xPN-1 in the developing neural plate/tube is consistent with expression previously reported for mouse PN-1 and chick Pn-1 (Kury et al., 1997; Mansuy et al., 1993; Rodriguez-Niedenfuhr et al., 2003) . Expression of PN-1 in the floorplate of brain and the otic vesicle is similar between Xenopus and mouse PN-1, but has not been reported for chick Pn-1. Expression of PN-1 in the pharyngeal endoderm, on the other hand, is similar between Xenopus and chick, but not mouse embryos. The strong expression of xPN-1 in the notochord has not been reported for the PN-1 orthologues in chick or mouse embryos. While the common expression of vertebrate orthologues of PN-1 in the developing nervous system suggests some shared function of PN-1 in vertebrate development, distinctive regions of expression in the frog suggest the possible of divergent developmental functions of xPN-1 as well.
Ectopic expression of Xenopus PN-1 affects axis formation, animal cap elongation, and mesendoderm gene expression
To investigate the effect of ectopic xPN-1 on early embryogenesis, we examined the effect of varying the location of xPN-1 mRNA injection on embryonic development (Fig. 3) . Injection of 1 ng of xPN-1 RNA into two dorsal blastomeres at the four-cell stage caused defects in gastrulation movement with high efficiency (Fig. 3C ,F,L). These embryos showed incomplete epiboly during gastrulation, and the yolk plug remained open through neurula stages (Fig. 3C ). These embryos subsequently showed abnormal anterior-posterior axial elongation, but head formation was relatively normal (Fig. 3F) . In contrast to dorsal side injection, ventral side injection of 1 ng of xPN-1 RNA had little effect on embryogenesis (Fig. 3D,I ,L). At higher mRNA doses (2 ng), ventral injection resulted in gastrulation defects with reduced efficiency when compared to injection of 1 ng of xPN-1 on the dorsal side (Fig. 3L ). This result indicates that the dorsal and ventral regions of the embryo have different sensitivities to ectopic xPN-1.
The biochemical basis for previously reported activities of PN-1 has generally been thought to be its function as an inhibitor of serine proteases. To test whether this activity is important for the effects of xPN-1 on Xenopus development, we generated two mutants of xPN-1 predicted to lack protease inhibitory activity xPN-1 pm and xPN-1 DC (Fig. 3A) . xPN-1 pm has the mutations Arg362Pro and Ser363Pro, which are correspond to residues P1 and P1 0 of the serine protease cleavage site in the RCL (Nick et al., 1990; Silverman et al., 2001) . The introduction of prolines at P1 and P1 0 of the scissile site have previously been reported to eliminate the protease inhibition activity of the Drosophila Serpin gene, Spn27A, (Ligoxygakis et al., 2003) . xPN-1 DC encodes a C-terminally truncated protein that lacks the entire RCL, which is essential for both non-covalent and covalent binding of serpins to their target proteases (Gettins, 2002) . We compared the activities of the two xPN-1 mutants to wild type xPN-1 by ectopic expression in the prospective dorsal or ventral side of early embryos. Surprisingly, both xPN-1 pm and xPN-1 DC caused gastrulation and axis formation defects identical to those caused by intact xPN-1 (Fig. 3G,H ). While xPN-1 pm showed weaker activity than intact xPN-1, xPN-1 DC was as potent as wild type xPN-1 in causing defects (Fig. 3L ). Ventral side injections of both mutants also had less activity than dorsal side injections (Fig. 3J-L ). These observations demonstrate that the effects of xPN-1 on early Xenopus development are independent on its serine protease inhibitory activity. To further characterize the effects of xPN-1 on embryogenesis, we examined the effect of ectopic xPN-1 on mesodermal cell movements and mesendoderm specification in animal caps induced by activin. mRNAs encoding activin and xPN-1 were co-injected into the animal pole region at the two-cell stage and animal caps were dissected from the embryos at Stage 9. While animal caps expressing activin and an EGFP control showed elongation characteristic of mesoderm induction (Smith et al., 1988 ) (97% elongation, nZ37), co-injection of xPN-1 with activin strongly inhibited this elongation (0% elongation, nZ 37) (Fig. 4A,B) . In addition, both the processing site mutant, xPN-1 pm and the RCL deletion mutant xPN-1 DC had effects on animal cap elongation similar to wild type xPN-1 (3% elongation, nZ35 and 8% elongation, nZ37, respectively), (Fig. 4C,D) . These results confirm that this activity of xPN-1 is independent of the protease-inhibitory domain. xPN-1, xPN-1 pm or xPN-1 DC RNA injection alone did not induce animal cap elongation (0%, nZ37, 0%, nZ36, 0%, nZ37, respectively), (Fig. 4G-I ). These observations indicate that ectopic xPN-1 can inhibit the convergent extension movement characteristic of mesoderm induction in animal caps.
To examine the effects of xPN-1 on mesendoderm specification, we tested the effect of co-injection of mRNA encoding wild type xPN-1 or these xPN-1 mutants, together with activin RNA, on the induction of mesendodermal markers in animal caps. xPN-1 inhibited the induction of Xbra, chordin and cerberus by activin at Stage 10.5, but had no effect on induction of goosecoid or Xnr1 (Fig. 4J) . The RCL deletion mutant xPN-1 DC had inhibitory effects on the induction of Xbra, chordin and cerberus similar to wild type xPN-1. The processing site mutant, xPN-1 pm, inhibited expression of Xbra and chordin, but showed limited inhibition of cerberus expression. The somewhat weaker activity of xPN-1 pm in this assay is consistent with the weaker effects of this mutant on whole embryos when compared to xPN-1 and xPN-1 DC. At tailbud stage, co-injection of xPN-1, xPN-1 pm or xPN-1 DC with activin inhibited muscle actin expression, but had no effect on expression of the notochord marker collagen type II or the endodermal marker endodermin (Fig. 4K) . While the effects of xPN-1 on mesendodermal markers clearly demonstrate that it can modify mesendodermal specification, the sets of genes that are affected or unaffected by xPN-1 do not fall into any clear pattern with regard to signaling pathways or regional expression. For example, chordin, which is inhibited by xPN-1, and goosecoid, which is not, are both dorsal mesodermal markers dependent on both nodal-related and Wnt signaling for their expression. Expression of xPN-1 or xPN-1 DC alone in animal caps strongly induced the cement gland markers Otx2 and AG1, weakly induced the neural marker NCAM, but did induce mesodermal or endodermal markers (Fig. 4G) . xPN-1 pm alone also induced Otx2 and AG1 weakly. These effects on isolated prospective ectoderm are all consistent with a weak neutralizing activity of either wild type xPN-1 or the xPN-1 mutants.
We also examined the effects of xPN-1 expression on mesendoderm specification in whole embryos. We carried out in situ hybridization for the detection of early mesendoderm markers in embryos injected on the dorsal side with RNA encoding xPN-1 or the two xPN-1 mutants (Fig. 5) . xPN-1and xPN-1 (B) , xPN-1 pm (C) or xPN-1 DC RNA (D), or injected with 2 ng of EGFP (F), xPN-1 (G), xPN-1 pm (H) or xPN-1 DC RNA (I) alone, and were dissected for animal cap assay at Stage 9. Uninjected caps were used as a control (E). (J) RT-PCR of animal caps co-injected with 1 pg of activin RNA plus 2 ng of EGFP, xPN-1, xPN-1 pm or xPN-1 DC RNA at Stage 10.5. xPN-1 and both mutants of xPN-1 inhibited expression of Xbra, chordin (chd) and cerberus (cer), but not goosecoid (gsc) or Xnr1, induced by activin. xPN-1, xPN-1 pm or xPN-1 DC alone did not induce any mesendoderm gene expression. (K) RT-PCR of animal caps co-injected with 1 pg of activin RNA plus 2 ng of EGFP, xPN-1, xPN-1 pm or xPN-1 DC RNA at Stage 30. xPN-1 and both mutants of xPN-1 inhibited expression of muscle specific actin (m-actin), but not collagen type II (Col II) or endodermin (edd), induced by activin. xPN-1 and xPN-1 DC induced expression of NCAM, Otx2 and XAG-1 when injected alone, while xPN-1 pm induced expression of Otx2 and XAG-1 when injected alone. Neither wild type nor mutants xPN-1 expression induced mesendodermal genes in animal caps. WE, whole embryo positive control; RT-, reverse transcriptase minus negative control in EF-1 a PCR.
xPN-1 DC had inhibitory effects on the induction of Xbra and cerberus in embryos similar to those observed in activininduced animal caps, but did not inhibit expression of chordin, goosecoid or Xnr1 (Fig. 5B,D,F ,H,J,L,N,P,R,T). The lack of effect of xPN-1 on goosecoid and Xnr1 expression in intact embryos is also consistent with the results from the animal cap assay (Fig. 4J) . Chordin expression in intact embryos was not inhibited by xPN-1 in embryos but was inhibited in activin-induced animal caps, indicating that the xPN-1 resistant endogenous signaling pathways are sufficient to promote endogenous Chordin expression. The processing site mutant, xPN-1 pm inhibited the expression of Xbra weakly and did not affected the expression of other genes in intact embryos, consistent with the weaker effects of this mutant compared with xPN-1 and xPN-1 DC (Fig. 5C ,G,K,O,S).
We report here the endogenous expression of xPN-1 and its activity in modifying both cell movements and germ layer specification in gastrula stage Xenopus embryos. Most significantly, these activities of xPN-1 are independent of its function as a serine protease inhibitor, and suggest that there must be a novel mechanism by which ectopic expression of this factor modulates early developmental processes. Precedent for this possibility is provided by PEDF, another serpin family member that lacks serine protease inhibitory activity and which, like xPN-1, has neuroprotective activity. The mechanism of PEDF action is unknown, however, and our studies suggest that the frog embryo will provide a useful assay system for investigating alternative modes of action of serpin family members. Identification of signaling pathways modulated by xPN-1 in the early embryo, and determination of the necessity of endogenous xPN-1 for normal development, should help to clarify the functional significance of proteaseindependent actions of serpins.
Experimental procedures
Expression screening, microinjection and plasmid construction of xPN-1
Expression screening was carried out by microinjection of synthesized mRNA into both blastomeres of two-cell stage Xenopus embryos. Synthetic mRNAs were made using SP6 mMESSAGE mMACHINE Kit (Ambion). 96 pools of mRNAs containing each 32 clones were synthesized from a fulllength, normalized library of Xenopus egg cDNA (Salic et al., 2004) . Pools, which had biological activity, were subdivided and screened until single active clones were isolated. The xPN-1 cDNA clone was isolated by this approach and sequenced (GenBank accession number DQ324047). The ORF region of xPN-1 was subcloned into pCS2Cvector. pCS2CxPN-1 pm and pCS2CxPN-1 DC were generated by PCR based mutagenesis; Arg362 and Ser363 to Pro362 and Pro363 in pCS2CxPN-1 pm, Thr349 to termination codon in pCS2CxPN-1 DC. All constructs generated by PCR amplification were sequence-verified. For phenotype observation, embryos were injected with various xPN-1 RNAs into the dorsal or ventral marginal region of two blastomeres at four-cell stage, and counted at stage 16 based on incompleteness of epiboly.
Animal cap assay and semi-quantitative RT-PCR
X. laevis embryos were obtained by artificial fertilization and embryos were staged according to Nieuwkoop and Faber (1956) . For the animal cap assay, synthesized RNA was microinjected into the animal side of both blastomeres of two-cell-stage embryos. Animal caps were dissected from Stage 9 blastulae and were cultured until stage 20 for elongation assay, until stage 10.5 (early gastrula stage) and stage 30 (tailbud stage) for RT-PCR.
For RT-PCR, total RNA was isolated from various developmental stages' embryos or animal caps by TRIZOL (Invitrogen), and 1 mg of total RNA was used for RT reaction according to Watanabe and Whitman (1999) . One twentieth of the cDNA was used as a template in semi-quantative PCR analysis. Used primers were xPN-1 (forward, 5 0 -CATCCAAGGCAGGAGATGAT-3 0 ;
reverse, 5 0 -GATGGGGTCAGCGACTCCTA-3 0 ), ornithine decarboxylase (ODC) and Otx2 (http://www.xenbase.org/), Xbra and goosecoid (HemmatiBrivanlou and Melton, 1994) , chordin (Suzuki et al., 1997) , cerberus (Bouwmeester et al., 1996) , Xnr1 (Lustig et al., 1996) , EF-1 a and muscle actin . NCAM (Wawersik et al., 2005) , XAG1 (Gammill and Sive, 1997), collagen type II (Takahashi et al., 2000) and endodermin (Watanabe and Whitman, 1999) . PCR products were separated by agarose gel electrophoreses and detected by ethidium bromide staining. PCR products of xPN-1 were recovered from gels and confirmed by sequencing.
In situ hybridization analysis
In situ hybridization analysis was performed according to Sive et al. (2000) , modified by the addition of 0.3% CHAPS in 2XSCC and 0.2XSSC for probe washing. Plasmids used for probe synthesis were xPN-1 (the cloning vector in this work), psp73-Xbra (Smith et al., 1991) , pBluescript SK(K)-goosecoid (Cho et al., 1991) , pBluescript SK(K)-chordin (Sasai et al., 1994) , cerberus (Bouwmeester et al., 1996) and pCRII-Xnr1 (Onuma et al., 2006) . After staining, embryos were bleached, cleared with benzyl benzoate/benzyl alcohol (2:1) or dissected with a surgical knife. Identification of organs and tissues was carried out according to Bernardini et al. (1999) .
